-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3942 Impact of Platelet Transfusion and Bleeding Risk Stratification in Patients with Immune Thrombocytopenia before Procedures: A Nationwide Population-Based Cohort Study

Program: Oral and Poster Abstracts
Session: 311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster III
Hematology Disease Topics & Pathways:
Research, Bleeding and Clotting, Clinical Research, Platelet disorders, Supportive Care, Diseases, Real-world evidence, Treatment Considerations, Technology and Procedures, Study Population, Human, Machine learning
Monday, December 9, 2024, 6:00 PM-8:00 PM

Ka-Won Kang, MD, PhD1*, Yumin Choi2*, Hyung-Jun Lim3*, Kunye Kwak, MD4*, Yoon Seok Choi, MD, PhD1, Yong Park, MD, PhD1, Byung Soo Kim, MD, PhD1*, Kwang-Sig Lee5* and Ki Hoon Ahn6*

1Division of Hematology-Oncology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea, Republic of (South)
2School of Mechanical Engineering, Korea University, Seoul, Korea, Republic of (South)
3Graduate School of SW&AI Convergence, Korea University, Seoul, Korea, Republic of (South)
4Division of Hematology-Oncology, Department of Internal Medicine, Korea University College of Medicine, Seoul, AL, South Korea
5AI Center, Korea University College of Medicine, Seoul, Korea, Republic of (South)
6Department of Obstetrics & Gynecology, Anam Hospital, Korea University College of Medicine, Seoul, Korea, Republic of (South)

Background: The main treatment goal for immune thrombocytopenia (ITP) is to reduce bleeding risk, requiring extra precautions during procedures. Adjusting platelet thresholds with ITP treatments is usually recommended, but platelet transfusions are commonly used despite their controversial benefits. This study aims to evaluate the effectiveness of platelet transfusion in reducing post-procedure bleeding risk and to identify predictive indicators of post-procedure bleeding.

Methods: This study used a nationally representative database to develop a model to predict the risk of post-procedure bleeding in patients with ITP. Machine learning analyses, including random forest feature importance and Shapley additive explanations (SHAP) values, were employed. This contained a total of 34 post-procedural bleeding risk factors, including the amount of platelet transfusion.

Results: The random forest model had an area under the receiver-operating characteristic curve of 93.6%. The analysis identified the following variables as most important: amount of platelet transfusion, high-risk procedure, use of anticoagulant drugs, no use of antiplatelet or anticoagulant drugs, anemia, age, low-risk procedure, moderate-risk procedure, ITP treatment, and newly diagnosed ITP. Amount of platelet transfusion, high-risk procedures, use of anticoagulant drugs, anemia, ITP treatment, and newly diagnosed ITP positively correlated with post-procedure bleeding risk. In contrast, no use of antiplatelet or anticoagulant drugs and moderate- or low-risk procedures were negatively associated with post-procedure bleeding risk. In the SHAP dependence plot, the amount of platelet transfusion was associated with high-risk procedures. Additionally, among patients undergoing high-risk procedures, the likelihood of post-procedure bleeding increased with age.

Conclusions: Platelet transfusion does not significantly reduce the risk of post-procedural bleeding in patients with ITP. The risk of post-procedural bleeding is more closely related to the bleeding risk of the procedure and the patient's medical condition. Minimizing inappropriate platelet transfusions and addressing factors that can increase bleeding risk before procedures are crucial.

Keywords: Immune thrombocytopenia, Procedure, Platelet transfusion, Bleeding risk, Machine learning analysis

Disclosures: No relevant conflicts of interest to declare.

*signifies non-member of ASH